138 related articles for article (PubMed ID: 34731765)
1. P2Y
Al-Najjar BO; Saqallah FG; Abbas MA; Al-Hijazeen SZ; Sibai OA
Eur J Med Chem; 2022 Jan; 227():113924. PubMed ID: 34731765
[TBL] [Abstract][Full Text] [Related]
2. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL
Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064
[TBL] [Abstract][Full Text] [Related]
3. Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist.
Ahn YH; Lee JY; Park HD; Kim TH; Park MC; Choi G; Kim S
Molecules; 2016 Aug; 21(9):. PubMed ID: 27563870
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
[TBL] [Abstract][Full Text] [Related]
5. Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y
Liu X; Gao ZG; Wu Y; Stevens RC; Jacobson KA; Zhao S
Sci Rep; 2018 May; 8(1):8084. PubMed ID: 29795391
[TBL] [Abstract][Full Text] [Related]
6. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays.
Leunissen TC; Wisman PP; van Holten TC; de Groot PG; Korporaal SJ; Koekman AC; Moll FL; Teraa M; Verhaar MC; de Borst GJ; Urbanus RT; Roest M
Platelets; 2017 Sep; 28(6):567-575. PubMed ID: 27885904
[TBL] [Abstract][Full Text] [Related]
7. Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y
Lei Y; Zhang B; Liu D; Zhao J; Dai X; Gao J; Mao Q; Feng Y; Zhao J; Lin F; Duan Y; Zhang Y; Bao Z; Yang Y; Mou Y; Wang S
J Med Chem; 2020 Dec; 63(24):15752-15772. PubMed ID: 33307675
[TBL] [Abstract][Full Text] [Related]
8. P2Y
Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
[TBL] [Abstract][Full Text] [Related]
9. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
11. Significant Discovery of Tetrahydrothieno[3,2-c]pyridine-2-carboxamide Analogs as Potent P2Y12 Receptor Antagonists.
Bhalekar SB; Shelke SN
Chem Biodivers; 2019 Apr; 16(4):e1800550. PubMed ID: 30629808
[TBL] [Abstract][Full Text] [Related]
12. Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y
Gündüz D; Tanislav C; Sedding D; Parahuleva M; Santoso S; Troidl C; Hamm CW; Aslam M
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146050
[TBL] [Abstract][Full Text] [Related]
13. A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs.
Fayaz SM; Rajanikant GK
Curr Pharm Des; 2012; 18(12):1625-34. PubMed ID: 22360514
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance.
Dorsam RT; Murugappan S; Ding Z; Kunapuli SP
Hematology; 2003 Dec; 8(6):359-65. PubMed ID: 14668029
[No Abstract] [Full Text] [Related]
15. Antithrombotic P2Y
Baqi Y; Müller CE
Drug Discov Today; 2019 Jan; 24(1):325-333. PubMed ID: 30291899
[TBL] [Abstract][Full Text] [Related]
16. The role of P2Y₁₂ receptor and activated platelets during inflammation.
Liverani E; Kilpatrick LE; Tsygankov AY; Kunapuli SP
Curr Drug Targets; 2014; 15(7):720-8. PubMed ID: 24845219
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of action for reversible P2Y12 antagonists.
Liu H; Ge H; Peng Y; Xiao P; Xu J
Biophys Chem; 2011 May; 155(2-3):74-81. PubMed ID: 21440362
[TBL] [Abstract][Full Text] [Related]
18. Docking-based virtual screening of potential human P2Y12 receptor antagonists.
Chen H; Dong X; Zhou M; Shi H; Luo X
Acta Biochim Biophys Sin (Shanghai); 2011 May; 43(5):400-8. PubMed ID: 21474491
[TBL] [Abstract][Full Text] [Related]
19. Investigating the binding mechanism of novel 6-aminonicotinate-based antagonists with P2Y
Zhou S; Fang D; Tan S; Lin W; Wu W; Zheng K
J Biomol Struct Dyn; 2017 Oct; 35(13):2938-2965. PubMed ID: 27634290
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.
Yang W; Wang Y; Lai A; Qiao JX; Wang TC; Hua J; Price LA; Shen H; Chen XQ; Wong P; Crain E; Watson C; Huang CS; Seiffert DA; Rehfuss R; Wexler RR; Lam PY
J Med Chem; 2014 Jul; 57(14):6150-64. PubMed ID: 24931384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
